PMID: 8959033Oct 31, 1996Paper

Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents

Annals of the New York Academy of Sciences
S F AliW Slikker

Abstract

1. Multiple injections of METH (4 x 10 mg/kg, i.p.) at room temperature (23 degrees C) produced a significant depletion of dopamine (DA) and its metabolites DOPAC and HVA in striatum at 24 and 72 hr, and 1 and 2 wk. 2. Three days post 4 x 10 mg/kg METH at 23 degrees C, an 80% decrease in striatal dopamine (DA) occurred, while the same dose at 4 degrees C produced only a 20% DA decrease, and 4 x 20 mg/kg METH at 4 degrees C produced a 54% DA decrease. A similar pattern in the decreases of the DA metabolites DOPAC and HVA was observed after METH administration. 3. At 23 degrees C (+)MK-801 completely blocked while phenobarbital (40% decrease) and diazepam (65% decrease) partially blocked decreases in striatal DA produced by 4 x 10 mg/kg METH. Decreases in DOPAC and HVA were similar to the decreases in DA after METH and antagonists. 4. Multiple injections of METH (4 x 10 mg/kg, i.p.) at room temperature also produced a significant depletion of serotonin (5-HT) in striatum at 24 and 72 hr, and 1 and 2 wk. The depletion of 5-HT metabolite 5-HIAA was found only at 72 hr post-dosing. 5. This depletion of 5-HT and its metabolite 5-HIAA at room temperature was blocked either by changing the environmental temperature to 4 degrees C, or b...Continue Reading

References

Dec 1, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·J W Gibb, F J Kogan
Feb 1, 1976·Drug and Alcohol Dependence·L S SeidenC R Schuster
Apr 1, 1992·Archives of Neurology·A M Buchan
Nov 1, 1992·Journal of Neurobiology·D W Choi
Apr 30, 1990·Brain Research·D CorbettR A Jonas
Apr 1, 1982·Biochemical Pharmacology·F N Minard, D S Grant
Aug 1, 1995·Molecular Neurobiology·J L CadetC J Epstein

❮ Previous
Next ❯

Citations

Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jie YuanGeorge A Ricaurte
Feb 24, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Seog Ju KimPerry F Renshaw
Oct 18, 2000·Journal of Neurochemistry·J M KokoshkaG R Hanson
Aug 27, 2010·Journal of Pineal Research·Chutikorn NopparatPiyarat Govitrapong
Jul 17, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David S SegalArthur K Cho
Mar 6, 2010·Annals of the New York Academy of Sciences·Bryan K YamamotoGary A Gudelsky
Dec 31, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Rocío M De PablosAlberto Machado
Apr 13, 2007·European Journal of Applied Physiology·Eugene A Kiyatkin
Jan 30, 2004·The Journal of Pharmacology and Experimental Therapeutics·Kamisha L Johnson-DavisDiana G Wilkins
Aug 23, 2001·Brain Research. Brain Research Reviews·C DavidsonE H Ellinwood
Dec 9, 2003·European Journal of Pharmacology·Kamisha L Johnson-DavisDiana G Wilkins
Mar 31, 2009·Brain Research Reviews·Irina N Krasnova, Jean Lud Cadet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.